DDAVP NASAL SUMMARY
DDAVP® Nasal Spray (desmopressin acetate) is a synthetic analogue of the natural pituitary hormone 8-arginine vasopressin (ADH), an antidiuretic hormone affecting renal water conservation.
DDAVP Nasal Spray is indicated for the following:
Primary Nocturnal Enuresis: DDAVP Nasal Spray is indicated for the management of primary nocturnal enuresis. It may be used alone or adjunctive to behavioral conditioning or other nonpharmacological intervention. It has been shown to be effective in some cases that are refractory to conventional therapies.
Central Cranial Diabetes Insipidus: DDAVP Nasal Spray is indicated as antidiuretic replacement therapy in the management of central cranial diabetes insipidus and for management of the temporary polyuria and polydipsia following head trauma or surgery in the pituitary region. It is ineffective for the treatment of nephrogenic diabetes insipidus.
The use of DDAVP Nasal Spray in patients with an established diagnosis will result in a reduction in urinary output with increase in urine osmolality and a decrease in plasma osmolality. This will allow the resumption of a more normal life-style with a decrease in urinary frequency and nocturia.
There are reports of an occasional change in response with time, usually greater than 6 months. Some patients may show a decreased responsiveness, others a shortened duration of effect. There is no evidence this effect is due to the development of binding antibodies but may be due to a local inactivation of the peptide.
Patients are selected for therapy by establishing the diagnosis by means of the water deprivation test, the hypertonic saline infusion test, and/or the response to antidiuretic hormone. Continued response to intranasal DDAVP can be monitored by urine volume and osmolality.
DDAVP is also available as a solution for injection when the intranasal route may be compromised. These situations include nasal congestion and blockage, nasal discharge, atrophy of nasal mucosa, and severe atrophic rhinitis. Intranasal delivery may also be inappropriate where there is an impaired level of consciousness. In addition, cranial surgical procedures, such as transphenoidal hypophysectomy create situations where an alternative route of administration is needed as in cases of nasal packing or recovery from surgery.
Media Articles Related to Ddavp Nasal (Desmopressin)
FDA Panel Backs Nasal Spray for Nocturnal Polyuria
Source: MedPage Today OB/Gyn [2016.10.19]
(MedPage Today) -- Support for intransal desmopressin despite reservations
Published Studies Related to Ddavp Nasal (Desmopressin)
Desmopressin and oxybutynin in monosymptomatic nocturnal enuresis: a randomized,
double-blind, placebo-controlled trial and an assessment of predictive factors. 
evaluated... CONCLUSIONS: Our findings highlight that anticholinergic agents may play an
Efficacy and safety of desmopressin for treatment of nocturia: a systematic review and meta-analysis of double-blinded trials. [2011.09.07]
PURPOSE: The purpose of this analysis was to evaluate the efficacy and safety of desmopressin for the treatment of nocturia... CONCLUSIONS: Administered desmopressin was an effective and well-tolerated treatment for nocturia.
Desmopressin acetate in percutaneous ultrasound-guided kidney biopsy: a randomized controlled trial. [2011.06]
BACKGROUND: Bleeding complications occur in one-third of percutaneous kidney biopsies and increase costs of the hospital stay. The aim of the study was to evaluate the effect of prebiopsy administration of desmopressin acetate versus placebo in the incidence of postbiopsy bleeding complications... CONCLUSIONS: Prebiopsy desmopressin administration decreases the risk of bleeding and hematoma size in patients undergoing percutaneous kidney biopsy without a cost increase. Copyright (c) 2011 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.
Patients with severe aortic valve stenosis and impaired platelet function benefit from preoperative desmopressin infusion. [2011.05]
BACKGROUND: Patients with severe aortic valve stenosis have a markedly reduced platelet function as measured by a prolonged collagen adenosine diphosphate closure time (CADP-CT) determined by the platelet function analyzer PFA-100. We hypothesized that such patients may benefit from desmopressin when they present with prolonged CADP-CT due to the specific action of desmopressin on von Willebrand factor (VWF) and CADP-CT... CONCLUSIONS: Prolonged CADP-CT indicates platelet dysfunction in severe aortic valve stenosis, and can guide the use of desmopressin as an effective prohemostatic agent in patients with severe aortic valve stenosis. Copyright (c) 2011 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved.
Reducing nocturia in the elderly: a randomized placebo-controlled trial of staggered furosemide and desmopressin. [2011.03]
AIMS: The purpose of this study was to investigate efficacy, safety, and impact on quality of sleep of staggered furosemide and desmopressin in the treatment of nocturia in the elderly... CONCLUSIONS: Staggered furosemide and desmopressin provide an effective and well-tolerated treatment for nocturia in the elderly. Copyright (c) 2011 Wiley-Liss, Inc.
Clinical Trials Related to Ddavp Nasal (Desmopressin)
DDAVP in the Reduction of Post-operative Ecchymosis in Rhinoplasty [Not yet recruiting]
This is study looking at the use of a medication, Desmopressin acetate (DDAVP), to reduce
bleeding, swelling, and bruising in patients undergoing cosmetic nose surgery. DDAVP is a
drug used in patients with bleeding disorders. It works by activating molecules in the
blood stream called platelets that promote clotting. In the study, participants who are
have cosmetic nose surgery (rhinoplasty) will be randomly assigned to receive or not receive
medication. Photographs taken before and shortly after surgery will be evaluated for the
amount of bruising and swelling. Patients with heart, lung, kidney, or liver problems are
not eligible to participate.
Efficacy and Safety of IL-11 in DDAVP Unresponsive [Completed]
The purpose of this study is to determine the biologic efficacy and safety of rhIL-11 when
given subcutaneously in adults with moderate or mild hemophilia A or Von Willebrand disease
unresponsive to DDAVP. Biologic efficacy will be measured by the number and percent increase
of VWD coagulation tests (FVIII: C, VWF: Ag, VWF: RCo, closure time, APTT, and VWF multimers)
to the normal range, or at least to 1. 5-3 time baseline, following dosing of rhIL-11 when
given daily for 4 days, and boosted by DDAVP infusion on day 4, in those in whom DDAVP is
not contraindicated. Safety will be measured by the frequency of adverse events, including
fever, headache, fatigue, myalgias, arthralgias, fluid retention, or edema.
Characterization of Laboratory Response to DDAVP in Adult Hemophilia A Carriers [Enrolling by invitation]
The purpose of this study is to determine how female hemophilia A carriers respond to a
medication called DDAVP (Desmopressin).
The Effect of Gender on Antidiuresis - Evaluated by Graded Low Dose Desmopressin Infusion [Completed]
There is substantial evidence that women throughout life have significantly lower plasma
levels of the antidiuretic hormone vasopressin (pAVP) compared to men. The importance of
this is not yet fully elucidated, but in relation to the observations of lower pAVP levels,
no significant difference in renal response parameters was found. This could be interpreted
an increased renal sensitivity in females compared to males. The theory of increased renal
sensitivity in females is supported by a few pharmacodynamic studies currently available on
this topic. However none of the studies was designed with the purpose of investigate the
The aim of this study is to investigate possible gender differences in the renal sensitivity
to dDAVP and the effect of age on these differences. This will be done by low dose graded
infusion of the synthetic AVP analog dDAVP.
Participants are 80 healthy volunteers equally distributed between four age groups, 8-10
years of age, 16-18 years of age, 25-40 years og age and 65+ years of age.
Improving Platelet Activity for Cerebral Hemorrhage Treatment - DDAVP Proof of Concept [Completed]
The investigators intend to show that DDAVP improves platelet activity from baseline to 60
minutes after treatment start.
Page last updated: 2016-10-19